NCT05890287

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

An Open, Single-center, Exploratory Cohort Study of Chidamide in Combination With Endocrine in Maintenance Therapy After First-line Chemotherapy for HR+/HER2- Breast Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy and safety of Chidamide combined with endocrine for maintenance therapy after first-line chemotherapy for HR+/HER2- breast cancer

Detailed description

o explore the efficacy and safety of Chidamide combined with endocrine drug maintenance after first-line chemotherapy in the treatment of advanced untreated breast cancer; To explore the efficacy and safety of Chidamidecombined with endocrine drugs after first-line chemotherapy in the treatment of advanced first-line non-chemotherapeutic breast cancer after failure of CDK4/6 inhibitors

Conditions

• HR Positive HER2 Negative Advanced Breast Cancer

Interventions

Type	Name	Description
DRUG	Chidamide	Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen

Timeline

• Start date: 2023-05-16
• Primary completion: 2026-05-01
• Completion: 2026-10-01
• First posted: 2023-06-06
• Last updated: 2023-06-06

Locations

1 site across 1 country: China